Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1454-1459, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akaike, M.
Right arrow Articles by Matsumoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akaike, M.
Right arrow Articles by Matsumoto, T.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:1454-1459.)
© 2002 American Association for Clinical Chemistry, Inc.

Effect of Aspirin Treatment on Serum Concentrations of Lipoprotein(a) in Patients with Atherosclerotic Diseases

Masashi Akaike1a, Hiroyuki Azuma1, Ayako Kagawa1, Kazuya Matsumoto1, Ikuro Hayashi2, Katsuya Tamura3, Takeshi Nishiuchi4, Takahiko Iuchi1, Nobuyuki Takamori1, Ken-ichi Aihara1, Tomonori Yoshida1, Yasuhiko Kanagawa1 and Toshio Matsumoto1

1 Department of Medicine & Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima 770-8503, Japan.

2 Department of Cardiology, Tokushima Prefectural Hospital, Tokushima 770-8539, Japan.

3 Department of Cardiology, Health Insurance Naruto Hospital, Naruto 772-8503, Japan.

4 Kawashima Cardiovascular Clinic, Tokushima 770-0011, Japan.

aAddress correspondence to this author at: Department of Medicine & Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. Fax 81-88-633-7121; e-mail akaike{at}clin.med.tokushima-u.ac.jp.

Background: Increased serum lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerosis. We previously reported that aspirin reduced Lp(a) production by cultured hepatocytes via the reduction of apolipoprotein(a) [apo(a)] gene transcription.

Methods: We evaluated both the effect of aspirin treatment (81 mg/day) on serum Lp(a) concentrations and the correlation between the degree of reduction in serum Lp(a) and the type of apo(a) isoform in 70 patients with coronary artery disease or cerebral infarction.

Results: Aspirin lowered serum Lp(a) concentrations to ~80% of the baseline values in patients with high Lp(a) concentrations (>300 mg/L). The percentage of decrease in serum Lp(a) was larger in patients with high Lp(a) than in patients with low Lp(a) (<300 mg/L), irrespective of apo(a) isoform size. The decreases in serum Lp(a) in high Lp(a) patients with both the high-molecular-weight and the low-molecular-weight isoforms were positively correlated with the baseline Lp(a) concentrations.

Conclusions: Because the secretory efficiencies of apo(a) in the same isoform are likely to be similar, the difference in serum Lp(a) concentrations in patients having the same apo(a) isoform depends on the transcriptional activity of the apo(a) gene. These findings suggest that aspirin decreases serum Lp(a) concentrations via a decrease in apo(a) gene transcription more effectively in patients with high transcriptional activity of this gene.




The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S.-H. Lee, T. Rhim, Y.-S. Choi, J.-W. Min, S.-H. Kim, S.-Y. Cho, Y.-K. Paik, and C.-S. Park
Complement C3a and C4a Increased in Plasma of Patients with Aspirin-induced Asthma
Am. J. Respir. Crit. Care Med., February 15, 2006; 173(4): 370 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem., November 1, 2003; 49(11): 1785 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Liu, S.-P. Zhao, Y.-C. Cheng, and Y.-L. Li
Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease
Clin. Chem., August 1, 2003; 49(8): 1347 - 1352.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.